Pharmafile Logo

dimethyl glutamate

- PMLiVE

Torrid times at Gilead lead to calls for a major M&A deal

HIV portfolio sales down almost 10% to $7.5bn despite strong $533m start for Epclusa

- PMLiVE

Pfizer dropping bococizumab casts shadow over PCSK9 class

US payer resistance and diminishing efficacy prompt decision on would-be blockbuster

Sanofi reception

Manufacturing issues scupper Sanofi’s sarilumab launch plans

FDA turns down the rheumatoid arthritis drug’s marketing application after routine inspection

Bristol-Myers Squibb (BMS) building

Opdivo drives gain in BMS sales, but business revamp coming

Plans to invest in biologics production with potential divestment of older brands

- PMLiVE

GSK’s Bexsero vaccine growing fast, despite “tight” supply

Meningitis drug’s sales double as third quarter results exceed expectations

- PMLiVE

Study finds no problems switching from Remicade to biosimilar

Findings look to dispel ‘biosimilar resistance’ and encourage greater uptake

Eli Lilly HQ

Lilly promises solanezumab news in Alzheimer’s ‘before year-end’

If anti-amyloid drug proves effective, sales could reach $7.5bn according to analysts

Novartis Gehry Building

Novartis says its biosimilar sales should reach $1bn this year

Four-drug portfolio grew by 40% to $262m in the quarter

- PMLiVE

J&J’s Caruso bullish on Remicade defence plans

Believes top-selling arthritis treatment will weather introduction of biosimilars in US market

Deal Watch September 2016

Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up

- PMLiVE

Merck sees €2bn from new launches by 2022

Expects to deliver total sales of €4bn with multiple sclerosis, fertility and cancer drugs portfolio

Shire Basingstoke

Shire gives up on Momenta-partnered Humira biosimilar

Will fund programme for another 12 months while divesting ongoing activities to Momenta

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links